{"id":31136,"date":"2025-02-26T17:30:00","date_gmt":"2025-02-26T12:00:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31136"},"modified":"2025-05-01T16:25:06","modified_gmt":"2025-05-01T10:55:06","slug":"latest-breakthroughs-in-alzheimers-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment","title":{"rendered":"Alzheimer\u2019s Treatment: Latest Breakthroughs and Advancements in Therapeutic Development"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e60ae879dce\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e60ae879dce\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\/#KISUNLA_A_Breakthrough_in_Alzheimers_Disease_Treatment_and_the_Ongoing_Race_for_a_Cure\" >KISUNLA: A Breakthrough in Alzheimer\u2019s Disease Treatment and the Ongoing Race for a Cure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\/#Current_Commercial_Strategies_and_Innovations_in_Alzheimers_Disease_Treatment\" >Current Commercial Strategies and Innovations in Alzheimer\u2019s Disease Treatment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\/#February_2025\" >February 2025&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\/#January_2025\" >January 2025<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\/#December_2024\" >December 2024<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\/#October_2024\" >October 2024<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\/#September_2024\" >September 2024<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\/#Whats_Next_in_the_Azheimers_Disease_Treatment_Landscape\" >What\u2019s Next in the Azheimer\u2019s Disease Treatment Landscape?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Alzheimer\u2019s disease remains one of the most complex and devastating neurodegenerative disorders, affecting <strong>millions worldwide<\/strong> and placing an immense burden on patients, caregivers, and healthcare systems. Characterized by progressive cognitive decline, memory loss, and functional impairment, <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s disease<\/a> currently has <strong>no cure<\/strong>, making therapeutic innovation a critical priority. Traditional Alzheimer\u2019s treatments have long focused on symptom management, primarily through cholinesterase inhibitors and NMDA receptor antagonists. However, these approaches offer only temporary relief without addressing the underlying causes of neurodegeneration.<\/p>\n\n\n\n<p>In recent years, <strong>Alzheimer\u2019s research and drug development have entered a groundbreaking era<\/strong>, with disease-modifying therapies (DMTs) at the forefront of innovation. Novel therapeutics targeting <strong>amyloid-beta plaques, tau protein aggregation, neuroinflammation, and synaptic dysfunction<\/strong> are reshaping the Alzheimer\u2019s treatment landscape. Advances in <strong>monoclonal antibodies (mAbs), small molecules, gene therapy, and biomarker-driven approaches<\/strong> are not only improving diagnosis but also offering <strong>potential disease-modifying effects<\/strong> that could slow or even halt disease progression. The US FDA has already approved <strong>monoclonal antibodies such as Eisai and Biogen\u2019s LEQEMBI and ADUHELM<\/strong>, marking a significant step toward treating the root causes of Alzheimer\u2019s rather than just managing symptoms.<\/p>\n\n\n\n<p>The urgency for new treatments is underscored by <strong>the growing <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-epidemiology-forecast\"><strong>prevalence of Alzheimer\u2019s disease<\/strong><\/a>. In 2023, the <strong>7MM (United States, EU4 [Germany, France, Italy, Spain], the United Kingdom, and Japan) reported approximately 16 million diagnosed prevalent cases<\/strong>, a number expected to rise with aging populations. As Alzheimer\u2019s cases surge, the demand for innovative therapies that provide <strong>long-term efficacy, improved patient outcomes, and better disease management<\/strong> continues to grow.<\/p>\n\n\n\n<p>This article explores the <strong>latest breakthroughs in <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\"><strong>Alzheimer\u2019s treatment<\/strong><\/a>, highlighting <strong>emerging therapies, key drug developments, clinical advancements, and the evolving regulatory landscape<\/strong>. With a rapidly expanding Alzheimer\u2019s drug pipeline and new technologies shaping the future of treatment, <strong>hope is on the horizon for millions of patients and their families<\/strong>.<\/p>\n\n\n\n<p><strong><em>Want to dive deeper into Alzheimer\u2019s disease, its treatment landscape, and the latest innovations? Read our latest <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\"><strong><em>evergreen blog here<\/em><\/strong><\/a><strong><em>.<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-kisunla-a-breakthrough-in-alzheimer-s-disease-treatment-and-the-ongoing-race-for-a-cure\"><span class=\"ez-toc-section\" id=\"KISUNLA_A_Breakthrough_in_Alzheimers_Disease_Treatment_and_the_Ongoing_Race_for_a_Cure\"><\/span>KISUNLA: A Breakthrough in Alzheimer\u2019s Disease Treatment and the Ongoing Race for a Cure<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In <strong>July 2024<\/strong>, the <strong>FDA approved KISUNLA (donanemab-azbt)<\/strong>, marking a major milestone in the fight against <strong>Alzheimer\u2019s disease<\/strong>. Developed by <strong>Eli Lilly<\/strong>, <strong>KISUNLA <\/strong>became the first <strong>amyloid plaque-targeting therapy<\/strong> with evidence supporting <strong>treatment discontinuation once plaques are cleared<\/strong>, potentially <strong>reducing costs and infusion burden<\/strong> for patients.<\/p>\n\n\n\n<p>This approval signified <strong>a new era in Alzheimer&#8217;s treatment<\/strong>. In the <strong>TRAILBLAZER-ALZ 2 study<\/strong>, KISUNLA <strong>slowed cognitive decline by 35%<\/strong> in early-stage patients, with some showing <strong>a 39% lower risk of disease progression<\/strong>. More than just numbers, this breakthrough offered <strong>real hope<\/strong>\u2014a chance for patients to <strong>remember familiar faces a little longer, manage daily tasks more independently, and hold onto their identity despite the disease&#8217;s relentless grip<\/strong>.<\/p>\n\n\n\n<p>But <strong>KISUNLA <\/strong>is <strong><em>only part of the story<\/em><\/strong><em>. <\/em>The race to conquer Alzheimer&#8217;s is intensifying, with several biotech and pharma giants pushing boundaries, such as<strong> AB Science, Alzheon, AriBio, AgeneBio, Anavex Life Sciences, Annovis Bio, Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol Myers Squibb, Karuna Therapeutics, T3D Therapeutics,<\/strong> and others.\u00a0<\/p>\n\n\n\n<p>Despite <strong>decades of setbacks<\/strong>, the Alzheimer\u2019s research community remains <strong>relentless<\/strong>. The <strong>goal is no longer just slowing the disease\u2014it\u2019s stopping it altogether<\/strong>. While KISUNLA is a <strong>game-changer<\/strong>, the future holds even <strong>bigger breakthroughs<\/strong>. Scientists, drug developers, and patients alike are <strong>clinging to one powerful word: hope<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-commercial-strategies-and-innovations-in-alzheimer-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Current_Commercial_Strategies_and_Innovations_in_Alzheimers_Disease_Treatment\"><\/span>Current Commercial Strategies and Innovations in Alzheimer\u2019s Disease Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Along with hope, the relentless <strong>pursuit of a cure continues<\/strong>, driving <strong>rapid advancements<\/strong> in Alzheimer&#8217;s disease research. The treatment landscape is undergoing a <strong>transformative shift<\/strong>, with groundbreaking therapies emerging at an <strong>unprecedented pace<\/strong>. Recent breakthroughs are <strong>reshaping the market<\/strong>, offering new possibilities for patients, caregivers, and the broader healthcare community. As science pushes forward, so does the <strong>promise of better treatments, earlier diagnoses, and ultimately\u2014<\/strong><strong><em>a cure<\/em><\/strong><em>.<\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-february-2025-nbsp\"><span class=\"ez-toc-section\" id=\"February_2025\"><\/span>February 2025&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>On Feb 12, 2025,<strong> NKGen Biotech,<\/strong> a clinical-stage biotechnology company specializing in <strong>natural killer (NK) cell therapeutics<\/strong>, announced that the <strong>FDA has granted Fast Track designation<\/strong> for its investigational therapy, <strong>troculeucel<\/strong>, an ex vivo expanded autologous NK cell therapy for <strong>moderate Alzheimer\u2019s disease treatment<\/strong>. This designation aims to accelerate the development and regulatory review of <strong>Alzheimer\u2019s disease therapies<\/strong> that address serious unmet medical needs.<\/p>\n\n\n\n<p>According to <strong>Paul Y. Song, MD, Chairman and CEO of NKGen<\/strong>, the company specifically targeted <strong>moderate AD patients<\/strong>, who account for <strong>about 30% of Alzheimer\u2019s cases<\/strong>, as most current <strong>Alzheimer\u2019s disease treatments<\/strong> focus on early-stage patients. The <strong>FDA Fast Track designation<\/strong> follows promising results from a Phase I trial, showing early signs of clinical benefit. NKGen is now enrolling patients in its <strong>Phase IIa trial for moderate AD<\/strong> and anticipates sharing <strong>updated clinical data by the end of 2025<\/strong>. This milestone marks a step forward in <strong>Alzheimer\u2019s disease drugs development<\/strong>, potentially offering a <strong>novel AD treatment<\/strong> for patients in need.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-january-2025\"><span class=\"ez-toc-section\" id=\"January_2025\"><\/span>January 2025<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>On Jan 26, 2025,<\/strong> the <strong>FDA approved Eisai and Biogen\u2019s Supplemental Biologics License Application (sBLA)<\/strong> for <strong>LEQEMBI (lecanemab-irmb)<\/strong>, allowing for <strong>once-monthly maintenance dosing<\/strong> in patients with <strong>early-stage Alzheimer\u2019s disease<\/strong>. This approval offers a more convenient alternative to <strong>biweekly dosing<\/strong> after an <strong>18-month initiation phase<\/strong>, helping maintain clinical benefits while reducing treatment burden.<\/p>\n\n\n\n<p>LEQEMBI targets <strong>toxic amyloid protofibrils<\/strong>, a key factor in <strong>Alzheimer\u2019s disease progression<\/strong>. Clinical data from the <strong>Clarity AD trial<\/strong> showed that continued treatment <strong>slowed cognitive decline<\/strong>, reinforcing the importance of ongoing therapy. The drug is already <strong>approved in multiple countries<\/strong>, with additional regulatory reviews underway.<\/p>\n\n\n\n<p>Additionally, the <strong>FDA is reviewing a subcutaneous autoinjector version<\/strong> for <strong>weekly maintenance dosing<\/strong>, with a decision expected by <strong>August 31, 2025<\/strong>.<\/p>\n\n\n\n<p>Earlier on Jan 15, 2025, <strong>Spear Bio Inc.<\/strong> announced that the <strong>FDA <\/strong>granted <strong>Breakthrough Device Designation<\/strong> for its <strong>pTau 217 blood test<\/strong>, recognizing its potential to transform <strong>Alzheimer\u2019s disease diagnosis<\/strong>. The designation highlighted the test\u2019s ability to address a <strong>significant unmet need<\/strong> by providing a <strong>less invasive and more accessible alternative<\/strong> to conventional diagnostic methods, such as <strong>PET scans and lumbar punctures<\/strong>.<\/p>\n\n\n\n<p>The <strong>pTau 217 biomarker<\/strong> has been widely acknowledged for its role in <strong>Alzheimer\u2019s disease pathology<\/strong>, with support from leading research organizations, including the <strong>National Institute on Aging and the Alzheimer\u2019s Association<\/strong>. However, accurately detecting <strong>low levels of pTau 217 in plasma<\/strong> had remained a challenge. Spear Bio\u2019s <strong>SPEAR technology<\/strong> enabled <strong>highly sensitive and specific detection<\/strong>, allowing for <strong>earlier and more precise identification of Alzheimer\u2019s disease<\/strong>.<\/p>\n\n\n\n<p>By securing <strong>FDA Breakthrough Device Designation<\/strong>, Spear Bio strengthened its position in the <strong>neurodegenerative disease diagnostics space<\/strong>. This recognition underscored the potential of its <strong>advanced immunoassay platform<\/strong> to <strong>enhance patient management, accelerate diagnoses, and expand access to timely interventions and emerging Alzheimer\u2019s therapies<\/strong>.<\/p>\n\n\n\n<p><strong>Earlier in January 2025<\/strong>, BioArctic announced that the <strong>FDA<\/strong> had accepted Eisai\u2019s <strong>Biologics License Application (BLA)<\/strong> for the <strong>LEQEMBI subcutaneous autoinjector (SC-AI)<\/strong>, setting a <strong>PDUFA action date of August 31, 2025<\/strong>.<\/p>\n\n\n\n<p>LEQEMBI, an <strong>FDA-approved anti-amyloid therapy<\/strong> for <strong>early Alzheimer\u2019s disease<\/strong>, could become the <strong>first at-home subcutaneous treatment option<\/strong> if approved. The <strong>15-second injection process<\/strong> aims to enhance convenience, reducing the need for hospital visits.<\/p>\n\n\n\n<p>The BLA submission was supported by <strong>Clarity AD (Study 301) open-label extension (OLE) data<\/strong>. LEQEMBI is already approved in multiple countries, with <strong>EMA approval pending<\/strong>.<\/p>\n\n\n\n<p><strong><em>Want to dive deeper into the Alzheimer\u2019s drug pipeline and explore the next wave of potential breakthroughs?<\/em><\/strong><em> <\/em><a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\"><em>Read our latest blog now!<\/em><\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-december-2024\"><span class=\"ez-toc-section\" id=\"December_2024\"><\/span>December 2024<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>In December 2024<\/strong>, China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> approved <strong>Eli Lilly\u2019s KISUNLA<\/strong> for adults with <strong>early symptomatic Alzheimer\u2019s disease<\/strong>, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/mild-cognitive-impairment-market\"><strong>mild cognitive impairment<\/strong><\/a><strong> and <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/dementia-market\"><strong>mild dementia<\/strong><\/a> with confirmed <strong>amyloid pathology<\/strong>.<\/p>\n\n\n\n<p>China marks the <strong>fourth major approval<\/strong> for KISUNLA, following the <strong>U.S., Japan, and Great Britain<\/strong>, and arrives nearly a year after <strong>LEQEMBI<\/strong> gained approval. With a rapidly <strong>aging population<\/strong>, China is expected to be a significant market for <strong>anti-amyloid therapies<\/strong>.<\/p>\n\n\n\n<p>KISUNLA\u2019s approval is based on the <strong>TRAILBLAZER-ALZ 2 trial<\/strong>, where the drug <strong>slowed cognitive and functional decline by 35%<\/strong> versus placebo. Unlike LEQEMBI, KISUNLA is <strong>administered monthly<\/strong> and only until <strong>amyloid plaques are cleared<\/strong>, potentially reducing the treatment burden.<\/p>\n\n\n\n<p>Lilly aims to position KISUNLA as a <strong>key Alzheimer\u2019s therapy<\/strong>, despite concerns over cost and side effects. Meanwhile, uptake of <strong>anti-amyloid treatments<\/strong> remains under scrutiny, with <strong>physician opinions divided<\/strong> on their overall benefits.<\/p>\n\n\n\n<p><strong>Earlier in December 2024,<\/strong> the <strong>UK&#8217;s NICE<\/strong> ruled <strong>Eli Lilly\u2019s KISUNLA<\/strong> too expensive for <strong>NHS use<\/strong>, despite <strong>MHRA approval<\/strong>. The <strong>second approved Alzheimer\u2019s drug<\/strong> in the UK after <strong>LEQEMBI (lecanemab)<\/strong>, KISUNLA costs <strong>$32,000 per year in the U.S.<\/strong><\/p>\n\n\n\n<p>NICE deemed its <strong>benefits insufficient<\/strong> to justify NHS funding, estimating its <strong>cost-effectiveness at five to six times above<\/strong> the usual threshold. Given as a <strong>monthly infusion<\/strong>, KISUNLA slows <strong>cognitive decline by four to seven months<\/strong>, but NICE cited <strong>uncertainty<\/strong> about its <strong>long-term benefits<\/strong>.<\/p>\n\n\n\n<p>Lilly remains <strong>confident in KISUNLA\u2019s value<\/strong> and plans further discussions with NICE, which previously rejected <strong>LEQEMBI<\/strong> for similar reasons. If approved, KISUNLA could have reached <strong>70,000 eligible patients<\/strong> in England.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-october-2024\"><span class=\"ez-toc-section\" id=\"October_2024\"><\/span>October 2024<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>On <strong>October 10, 2024<\/strong>, <strong>Annovis Bio<\/strong> announced a <strong>successful End-of-Phase II meeting<\/strong> with the <strong>FDA<\/strong>, receiving clearance to advance its investigational drug, <strong>buntanetap<\/strong>, into <strong>pivotal Phase III trials<\/strong> for <strong>early Alzheimer\u2019s disease treatment<\/strong>.<\/p>\n\n\n\n<p>The <strong>Phase III program<\/strong> will consist of two studies:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A <strong>6-month trial<\/strong> to confirm buntanetap\u2019s <strong>symptomatic benefits<\/strong> in early AD.<\/li>\n\n\n\n<li>An <strong>18-month trial<\/strong> to evaluate its <strong>potential disease-modifying effects<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p>While both studies are planned, a <strong>well-conducted 6-month trial may be sufficient<\/strong> for an <strong>NDA filing within a year<\/strong> of initiation.<\/p>\n\n\n\n<p>The <strong>FDA raised no concerns<\/strong> regarding buntanetap\u2019s <strong>safety, liver enzymes, drug interactions, pharmacokinetics, or dose selection<\/strong> and approved the use of a <strong>new crystal form<\/strong> of the drug for further development.<\/p>\n\n\n\n<p><strong>Annovis Bio CEO Maria Maccecchini<\/strong> emphasized the company\u2019s commitment to <strong>launching the Phase III trial in early 2025<\/strong>, ensuring the study meets the highest standards to expedite regulatory approval and bring the therapy to patients as soon as possible.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-september-2024\"><span class=\"ez-toc-section\" id=\"September_2024\"><\/span>September 2024<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Earlier in <strong>2024<\/strong>, <strong>Eli Lilly<\/strong> secured <strong>Japanese approval<\/strong> for its <strong>Alzheimer\u2019s drug KISUNLA<\/strong>, marking its <strong>second major market<\/strong> after the <strong>U.S.<\/strong> The drug is indicated for <strong>early symptomatic Alzheimer\u2019s<\/strong>, including <strong>mild cognitive impairment (MCI) and mild dementia<\/strong> with confirmed amyloid pathology.<\/p>\n\n\n\n<p>Japan\u2019s <strong>rapidly aging population<\/strong> makes it a key market, with <strong>5 million dementia cases expected by 2030<\/strong>, two-thirds of which will be <strong>Alzheimer\u2019s<\/strong>.<\/p>\n\n\n\n<p>In the <strong>TRAILBLAZER-ALZ 2 study<\/strong>, KISUNLA <strong>slowed cognitive decline by 35%<\/strong> compared to placebo over <strong>18 months<\/strong>. Nearly <strong>half of the patients showed no clinical progression at one year<\/strong>, reinforcing its potential benefits.<\/p>\n\n\n\n<p>KISUNLA follows <strong>Eisai and Biogen\u2019s LEQEMBI (lecanemab)<\/strong>, which was approved in <strong>Japan a year earlier<\/strong>. Lilly highlights KISUNLA\u2019s <strong>fixed-duration treatment<\/strong>, stopping once <strong>amyloid plaques disappear<\/strong>, which may offer a <strong>cost advantage<\/strong> over continuous treatment options like LEQEMBI.<\/p>\n\n\n\n<p>While <strong>commercial success remains uncertain<\/strong>, KISUNLA&#8217;s <strong>U.S. sales performance<\/strong> will become clearer with <strong>Lilly\u2019s Q3 earnings update<\/strong>.<\/p>\n\n\n\n<p>From promising breakthroughs to global approvals, the <strong>Alzheimer\u2019s treatment landscape is evolving rapidly<\/strong>. While some therapies are gaining regulatory approval, others are making significant strides in clinical development, bringing us closer to transformative treatments.&nbsp;<\/p>\n\n\n\n<p><em>While some Alzheimer\u2019s disease drugs secure approvals and progress further,<\/em><strong><em> not all make it to the finish line.<\/em><\/strong><em> Discover the ones that fell short in 2024 in our latest blog. <\/em><a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-treatment-and-clinical-trials\"><strong><em>Failed Alzheimer\u2019s Drugs <\/em><\/strong><\/a><strong><em>\u2013 What Went Wrong?<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-s-next-in-the-azheimer-s-disease-treatment-landscape\"><span class=\"ez-toc-section\" id=\"Whats_Next_in_the_Azheimers_Disease_Treatment_Landscape\"><\/span>What\u2019s Next in the Azheimer\u2019s Disease Treatment Landscape?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><strong>Alzheimer\u2019s treatment landscape<\/strong><\/a> is experiencing a transformative shift, driven by groundbreaking therapies, regulatory milestones, and a deeper understanding of disease pathology. With the FDA approvals of <strong>KISUNLA <\/strong>and <strong>LEQEMBI<\/strong> paving the way, next-generation treatments like <strong>AB Science\u2019s Masitinib, Alzheon\u2019s Valiltramiprosate, AriBio\u2019s Mirodenafil, AgeneBio\u2019s Levetiracetam, Anavex Life Sciences\u2019 Blarcamesine, Annovis Bio\u2019s Buntanetap, Cerecin\u2019s Tricaprilin, BioVie\u2019s Bezisterim, and Cassava Sciences\u2019 Simufilam<\/strong> are pushing the boundaries of innovation. As the fight against Alzheimer\u2019s gains momentum, the future looks more hopeful than ever.<\/p>\n\n\n\n<p>While challenges remain\u2014<strong>ranging from cost and accessibility to long-term efficacy and safety concerns<\/strong>\u2014the <strong>momentum in Alzheimer\u2019s research has never been stronger<\/strong>. The relentless pursuit of <strong>disease-modifying therapies, improved diagnostics, and novel treatment strategies<\/strong> signals that the battle against Alzheimer\u2019s is far from over. <strong>With continued innovation, collaboration, and investment, the vision of halting or even reversing this devastating disease no longer seems out of reach.<\/strong><\/p>\n\n\n\n<p>For millions of patients and caregivers, these <strong>breakthroughs represent more than just scientific progress<\/strong>\u2014they offer <strong>tangible hope<\/strong> for a future where <strong>Alzheimer\u2019s is no longer an inevitable fate, but a conquerable challenge<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png\" alt=\"Alzheimer's Disease Market Outlook\" class=\"wp-image-31013\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer\u2019s disease remains one of the most complex and devastating neurodegenerative disorders, affecting millions worldwide and placing an immense burden on patients, caregivers, and healthcare systems. Characterized by progressive cognitive decline, memory loss, and functional impairment, Alzheimer\u2019s disease currently has no cure, making therapeutic innovation a critical priority. Traditional Alzheimer\u2019s treatments have long focused on [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31137,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19079,7145,6642,72,13307,20372,204,704,21071,22462],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-31136","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-aduhelm","tag-alzheimers-disease-market","tag-alzheimers-disease-pipeline","tag-alzheimers-disease","tag-alzheimers-disease-prevalence","tag-alzheimers-disease-treatment","tag-delveinsight","tag-fda","tag-leqembi","tag-recent-pharma-breakthroughs","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alzheimer\u2019s Treatment: Major Breakthroughs and Key Analysis<\/title>\n<meta name=\"description\" content=\"Stay updated on major breakthroughs in Alzheimer\u2019s treatment, from FDA-approved KISUNLA and LEQEMBI to emerging next-gen therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer\u2019s Treatment: Major Breakthroughs and Key Analysis\" \/>\n<meta property=\"og:description\" content=\"Stay updated on major breakthroughs in Alzheimer\u2019s treatment, from FDA-approved KISUNLA and LEQEMBI to emerging next-gen therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-26T12:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-01T10:55:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/26120607\/Alzheimers-Treatment-Latest-Breakthroughs-and-Advancements-in-Therapeutic-Development.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alzheimer\u2019s Treatment: Major Breakthroughs and Key Analysis","description":"Stay updated on major breakthroughs in Alzheimer\u2019s treatment, from FDA-approved KISUNLA and LEQEMBI to emerging next-gen therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment","og_locale":"en_US","og_type":"article","og_title":"Alzheimer\u2019s Treatment: Major Breakthroughs and Key Analysis","og_description":"Stay updated on major breakthroughs in Alzheimer\u2019s treatment, from FDA-approved KISUNLA and LEQEMBI to emerging next-gen therapies.","og_url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-26T12:00:00+00:00","article_modified_time":"2025-05-01T10:55:06+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/26120607\/Alzheimers-Treatment-Latest-Breakthroughs-and-Advancements-in-Therapeutic-Development.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment","url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment","name":"Alzheimer\u2019s Treatment: Major Breakthroughs and Key Analysis","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/26120607\/Alzheimers-Treatment-Latest-Breakthroughs-and-Advancements-in-Therapeutic-Development.png","datePublished":"2025-02-26T12:00:00+00:00","dateModified":"2025-05-01T10:55:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Stay updated on major breakthroughs in Alzheimer\u2019s treatment, from FDA-approved KISUNLA and LEQEMBI to emerging next-gen therapies.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-in-alzheimers-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/26120607\/Alzheimers-Treatment-Latest-Breakthroughs-and-Advancements-in-Therapeutic-Development.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/26120607\/Alzheimers-Treatment-Latest-Breakthroughs-and-Advancements-in-Therapeutic-Development.png","width":466,"height":284,"caption":"Alzheimer\u2019s Treatment Latest Breakthroughs and Advancements in Therapeutic Development"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/26120607\/Alzheimers-Treatment-Latest-Breakthroughs-and-Advancements-in-Therapeutic-Development-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Aduhelm<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Prevalence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Leqembi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">recent pharma breakthroughs<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aduhelm<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Prevalence<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Treatment<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Leqembi<\/span>","<span class=\"advgb-post-tax-term\">recent pharma breakthroughs<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Feb 26, 2025","modified":"Updated on May 1, 2025"},"absolute_dates_time":{"created":"Posted on Feb 26, 2025 5:30 pm","modified":"Updated on May 1, 2025 4:25 pm"},"featured_img_caption":"Alzheimer\u2019s Treatment Latest Breakthroughs and Advancements in Therapeutic Development","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31136"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31136\/revisions"}],"predecessor-version":[{"id":31138,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31136\/revisions\/31138"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31137"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31136"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31136"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}